Drug Trial Radar · NCT07851025
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
950
Planned (sponsor's estimate)
Start
Sep 16, 2026
Primary completion
Jun 28, 2030
Study completion Aug 29, 2033
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- European Network of Gynaecological Oncological Trial Groups (ENGOT); GOG Foundation
- First posted
- Oct 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy, safety and tolerability of Torvutatug samrotecan (torvu-sam) in combination with bevacizumab compared with bevacizumab monotherapy as first line maintenance treatment in patients with non-Homologous Recombination Deficient (non-HRD) positive advanced ovarian cancer.
Conditions
- Epithelial Ovarian Cancer
Interventions
Torvutatug samrotecanDrug
Antibody drug conjugate
BevacizumabDrug
Monoclonal antibody inhibitor of Vascular Endothelial Growth Factor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: up to approximately 5 years
Locations
220 sites in 29 countries. Site status is shown where the registry gives one.
Research Site
Tamarac, Florida · Not yet recruiting
Research Site
Tampa, Florida · Not yet recruiting
Research Site
Baton Rouge, Louisiana · Not yet recruiting
Research Site
Baltimore, Maryland · Not yet recruiting
Research Site
Billings, Montana · Not yet recruiting
Research Site
Cleveland, Ohio · Not yet recruiting
Research Site
Buenos Aires, Argentina · Not yet recruiting
Research Site
Buenos Aires, Argentina · Not yet recruiting
Research Site
Capital Federal, Argentina · Not yet recruiting
Research Site
Ciudad de Buenos Aires, Argentina · Not yet recruiting
Research Site
Ciudad de Buenos Aires, Argentina · Not yet recruiting
Research Site
Córdoba, Argentina · Not yet recruiting
Research Site
Córdoba, Argentina · Not yet recruiting
Research Site
Córdoba, Argentina · Not yet recruiting
Research Site
Rosario, Argentina · Not yet recruiting
Research Site
Salta, Argentina · Not yet recruiting
Research Site
Santa Fe, Argentina · Not yet recruiting
Research Site
Viedma, Argentina · Not yet recruiting
Research Site
Auchenflower, Australia · Recruiting
Research Site
Benowa, Australia · Not yet recruiting
Research Site
Hobart, Australia · Not yet recruiting
Research Site
Kingswood, Australia · Not yet recruiting
Research Site
Nedlands, Australia · Not yet recruiting
Research Site
Port Macquarie, Australia · Not yet recruiting
Research Site
Randwick, Australia · Not yet recruiting
Research Site
Richmond, Australia · Not yet recruiting
Research Site
Toorak Gardens, Australia · Not yet recruiting
Research Site
Wollongong, Australia · Not yet recruiting
Research Site
Woodville, Australia · Not yet recruiting
Research Site
Fortaleza, Brazil · Not yet recruiting
Research Site
Itajaí, Brazil · Not yet recruiting
Research Site
Jaú, Brazil · Not yet recruiting
Research Site
Natal, Brazil · Not yet recruiting
Research Site
Porto Alegre, Brazil · Not yet recruiting
Research Site
Rio de Janeiro, Brazil · Not yet recruiting
Research Site
Salvador, Brazil · Not yet recruiting
Research Site
São Paulo, Brazil · Not yet recruiting
Research Site
São Paulo, Brazil · Not yet recruiting
Research Site
São Paulo, Brazil · Not yet recruiting
Research Site
Dobrich, Bulgaria · Not yet recruiting
Showing 40 of 220 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.